Skip to main content
Top
Published in: Neurological Sciences 1/2013

01-05-2013 | SYMPOSIUM – BOTULINUMTOXINA (ALLERGAN) AND CHRONIC MIGRAINE: FROM TRIAL TO CLINICAL PRACTICE

Onabotulinum toxin A for treatment of chronic migraine with medication overuse

Author: L. Grazzi

Published in: Neurological Sciences | Special Issue 1/2013

Login to get access

Abstract

Chronic migraine is a common and debilitating headache syndrome. Botulinum neurotoxin (BoNT), a potent toxin produced by the anaerobic bacterium Clostridium botulinum, used largely for treatment of disorders associated with increased muscle tone and hyperidrosis, has been recently used for patients suffering from chronic migraine. In this study, two groups of patients were treated with different dosages of BoNT A to verify the efficacy for chronic migraine. The results confirmed the efficacy of BoNT A when used at the dosage of 150 U. In the second group of patients treated with 100 U, results were not significant. Although these results are preliminary, they led to intense efforts to evaluate the analgesic properties of BoNT A and to assess their clinical applicability.
Literature
1.
go back to reference Diener HC, Limmroth V (2004) Medication-overuse headache: a worldwide problem. Lancet Neurol 3:475–483PubMedCrossRef Diener HC, Limmroth V (2004) Medication-overuse headache: a worldwide problem. Lancet Neurol 3:475–483PubMedCrossRef
2.
go back to reference Grazzi L, Andrasik F, Usai S, Bussone G (2009) Treatment of chronic migraine with medication overuse: is drug withdrawal crucial? Neurol Sci 30(S1):85–88CrossRef Grazzi L, Andrasik F, Usai S, Bussone G (2009) Treatment of chronic migraine with medication overuse: is drug withdrawal crucial? Neurol Sci 30(S1):85–88CrossRef
3.
go back to reference Ranoux D, Attal N, Morain F, Bouhasira D (2008) Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008(64):274–283CrossRef Ranoux D, Attal N, Morain F, Bouhasira D (2008) Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008(64):274–283CrossRef
4.
go back to reference Mathew N, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C (2005) Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache. A randomized, double blind, placebo controlled trial. Headache 45:293–307PubMedCrossRef Mathew N, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C (2005) Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache. A randomized, double blind, placebo controlled trial. Headache 45:293–307PubMedCrossRef
5.
go back to reference Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G, Nappi G (2011) Botulinum toxin type-A in the prophylaxis treatment of medication-overuse headache: a multi center, double blind, randomized, placebo-controlled, parallel group study. J Head pain 12:427–433CrossRef Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G, Nappi G (2011) Botulinum toxin type-A in the prophylaxis treatment of medication-overuse headache: a multi center, double blind, randomized, placebo-controlled, parallel group study. J Head pain 12:427–433CrossRef
6.
go back to reference Blumenfeld A, Silberstein S, Dodick D, Aurora S, Turkel C, Binder W (2010) Method of injection of Onabotulinum toxin A for chronic migraine: a safe, well-tolerated and effective treatment paradigm based on the PREEMPT clinical program. Headache 50:1406–1418PubMedCrossRef Blumenfeld A, Silberstein S, Dodick D, Aurora S, Turkel C, Binder W (2010) Method of injection of Onabotulinum toxin A for chronic migraine: a safe, well-tolerated and effective treatment paradigm based on the PREEMPT clinical program. Headache 50:1406–1418PubMedCrossRef
7.
go back to reference Aoki KR (2005) Review of a proposed mechanisms for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26:785–793PubMedCrossRef Aoki KR (2005) Review of a proposed mechanisms for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26:785–793PubMedCrossRef
8.
go back to reference Aoki KR (2003) Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43(suppl):S9–S15PubMedCrossRef Aoki KR (2003) Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43(suppl):S9–S15PubMedCrossRef
9.
go back to reference Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L (2009) Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 141:60–69PubMedCrossRef Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L (2009) Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 141:60–69PubMedCrossRef
10.
go back to reference Headache Classification Subcommittee of the International Headache Society (2004) The International classification of headache disorders-2nd edition. Cephalalgia 24(suppl 1):1–160 Headache Classification Subcommittee of the International Headache Society (2004) The International classification of headache disorders-2nd edition. Cephalalgia 24(suppl 1):1–160
11.
go back to reference Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Goebel H, Lainez MJA, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ (2006) New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26:742–746PubMedCrossRef Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Goebel H, Lainez MJA, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ (2006) New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26:742–746PubMedCrossRef
Metadata
Title
Onabotulinum toxin A for treatment of chronic migraine with medication overuse
Author
L. Grazzi
Publication date
01-05-2013
Publisher
Springer Milan
Published in
Neurological Sciences / Issue Special Issue 1/2013
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-013-1381-1

Other articles of this Special Issue 1/2013

Neurological Sciences 1/2013 Go to the issue

PECULIAR CLINICAL ASPECTS OF MIGRAINE

Dopaminergic symptoms in migraine

TRIGEMINO AUTONOMICS CEPHALALGIAS (TACs)

SUNCT and SUNA: medical and surgical treatments